secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regenerative Medical Technology Group Inc. (RMTG)
CIK:        0001760026
Form:       8-K
Filed at:   2026-08-25T10:06:43+00:00
Accession:  0001213900-26-093220
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RMTG Q1 revenue up 90% YoY, Q2 quadrupled; Argentina license, Cancun lab expansion
--------------------------------------------------------------------------------

- Q1 2026 revenue up 90% YoY; Q2 revenue quadrupled YoY; 2025 total revenue $5.1M.
- Argentina granted first-ever license to harvest/produce biologics; Cancun lab added 2 clean rooms with COFEPRIS sign-off.
- ISSCA AI launched with 30 years of 60M redacted patient records to power physician tool.
- BKFC partnership continues; fighter Ben Rothwell treated; more announcements expected.
- Company evaluating capital raising strategies; may increase authorized shares; Nasdaq uplisting desired but no timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760026/000121390026093220/0001213900-26-093220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760026/000121390026093220/ea0303255-8k_regenerative.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-093220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer